0.32
-0.0048(-1.48%)
Currency In USD
| Previous Close | 0.33 |
| Open | 0.33 |
| Day High | 0.34 |
| Day Low | 0.32 |
| 52-Week High | 14.75 |
| 52-Week Low | 0.32 |
| Volume | 457,919 |
| Average Volume | 1.69M |
| Market Cap | 2.88M |
| PE | -0.01 |
| EPS | -22.01 |
| Moving Average 50 Days | 0.6 |
| Moving Average 200 Days | 4.12 |
| Change | -0 |
If you invested $1000 in Windtree Therapeutics, Inc. (WINT) 10 years ago, it would be worth $0 as of December 21, 2024 at a share price of $0.32. Whereas If you bought $1000 worth of Windtree Therapeutics, Inc. (WINT) shares 5 years ago, it would be worth $0.03 as of December 21, 2024 at a share price of $0.32.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Windtree Announces Istaroxime Presentation By Cardiogenic Shock Thought Leader At Cardiovascular Clinical Trials Conference
GlobeNewswire Inc.
Dec 16, 2024 1:00 PM GMT
WARRINGTON, Pa., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseas
Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia
GlobeNewswire Inc.
Dec 09, 2024 1:00 PM GMT
WARRINGTON, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseas
Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction
GlobeNewswire Inc.
Dec 04, 2024 1:00 PM GMT
WARRINGTON, Pa., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseas